Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06048653
Other study ID # P.T.REC/012/003942
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 2, 2022
Est. completion date February 2024

Study information

Verified date September 2023
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Diabetic peripheral neuropathy (DPN) occurs due to long standing hyperglycemia and associated metabolic derangements. Cognitive impairment is a common complication in diabetes mellitus. It is associated with a faster rate of cognitive decline.


Description:

This research aims to - determine the effect of non-invasive Vagus nerve stimulation on cognitive functions in diabetic peripheral neuropathy. - investigate the correlation between cognitive function and severity of diabetic neuropathy. - investigate the correlation between cognitive function and quality of life in diabetic peripheral neuropathy.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date February 2024
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 55 Years
Eligibility Inclusion Criteria: - patients with diabetic polyneuropathy - Female patients. - age ranges from 40 to 55 years old. - Duration of diabetic illness started since at least three years. - Patients with mild to moderate neuropathy according to Toronto clinical neuropathy score - Patients with cognitive function ranges from 24 - 15 score according to Mini mental state examination - Patients with HbA1c ranges from seven to nine score. - Ambulant patients with or without walking aids. - Medically and psychologically stable patients without cardiac problems, confirmed by Electro Cardiogram (ECG). - able to understand instructions. Exclusion Criteria: - Type I diabetes mellitus. - Severe visual, verbal or acoustic impairments. - Sever cognitive dysfunctions or that caused by other cause rather than diabetes mellitus. - Polyneuropathy caused by other cause rather than diabetes mellitus. - Other neurological problem as stroke. - Cardiovascular problems. - Metallic implants - Illiterate patients. - Uncooperative patients.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
A computer based cognitive rehabilitation program (Rehacom system)
Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction Patients will receive training for four weeks, two sessions per week. Each patient will assume a comfortable sitting position on a chair in front of the screen. A report will be generated at the end of the session. It will be used for follow up. Session duration will range from 45 to 60 min. including rest period.
Device:
Vagus nerve stimulation
stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.

Locations

Country Name City State
Egypt Faculty of Physical Therapy Giza

Sponsors (1)

Lead Sponsor Collaborator
heba ahmed khalifa

Country where clinical trial is conducted

Egypt, 

References & Publications (2)

Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004 Nov;26(8):1044-80. doi: 10.1080/13803390490514875. — View Citation

Broncel A, Bocian R, Klos-Wojtczak P, Kulbat-Warycha K, Konopacki J. Vagal nerve stimulation as a promising tool in the improvement of cognitive disorders. Brain Res Bull. 2020 Feb;155:37-47. doi: 10.1016/j.brainresbull.2019.11.011. Epub 2019 Nov 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Attention/ concentration score Rehacom will be used to assess score of attention/ concentration domain of cognitive function at baseline
Primary Attention/ concentration score Rehacom will be used to assess score of attention/ concentration domain of cognitive function post intervention (after one month)
Primary working memory score Rehacom will be used to assess score of working memory domain of cognitive function at baseline
Primary working memory score Rehacom will be used to assess score of working memory domain of cognitive function post intervention (after one month)
Primary Executive function score Rehacom will be used to assess score of executive function domain of cognitive function at baseline
Primary Executive function Rehacom will be used to assess score of executive function domain of cognitive function post intervention (after one month)
See also
  Status Clinical Trial Phase
Recruiting NCT04638556 - Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy
Completed NCT05580705 - Effects of Vibration Therapy in Addition to Routine Physical Therapy in Patients With Diabetic Neuropathy N/A
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Terminated NCT01620775 - MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain N/A
Completed NCT00835757 - Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy N/A
Recruiting NCT00553592 - Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes Phase 2
Recruiting NCT05863793 - Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy N/A
Withdrawn NCT05041816 - Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy N/A
Recruiting NCT06074562 - A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Recruiting NCT04457531 - LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy Early Phase 1
Completed NCT02947828 - Polyneuropathy in Diabetes Mellitus Type 2
Completed NCT02056431 - Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy N/A
Completed NCT01681290 - Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes Phase 2
Completed NCT01474772 - Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN) Phase 3
Completed NCT01086150 - Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy Phase 2/Phase 3
Completed NCT03447756 - Titration Study of ABX-1431 Phase 1
Completed NCT04688671 - Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain Phase 2
Completed NCT04984044 - Effect of Vitamin D in Patients With Diabetic Peripheral Neuropathy to Alleviate Pain and Improvement of Symptoms N/A
Completed NCT06130917 - Effects of Multisystem Exercise on Balance, Postural Stability, Mobility and Pain in Patients With DPN. N/A
Completed NCT01496365 - Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy Phase 2